Supply Chain Intelligence

BioAge Labs, Inc. Supply Chain

BIOA supply chain intelligence for BioAge Labs, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

BIOA ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

5Suppliers
18Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

BioAge Labs, Inc. (BIOA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

27Total relationships
2Distinct source URLs
10High confidence
0.756Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

BioAge Labs, Inc. Suppliers

TickerNameConfidenceEvidence
CITIGROUP-GLOBAL-MARKETS-INC CITIGROUP-GLOBAL-MARKETS-INC 92% the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
GOLDMAN-SACHS-CO-LLC GOLDMAN-SACHS-CO-LLC 92% the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
PIPER-SANDLER-CO PIPER-SANDLER-CO 92% the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
SVB-INNOVATIVE-CREDIT-GROWTH-FUND-IX-LP-AND-INNO SVB-INNOVATIVE-CREDIT-GROWTH-FUND-IX-LP-AND-INNO 92% In May 2022, we entered into a loan and security agreement (the Loan Agreement) with SVB Innovative Credit Growth Fund IX, LP and Innovative Credit Growth Fund VIII-A, LP pursuant to which we were ab…
GPCR Structure Therapeutics Inc. 72% Reciprocal relationship from GPCR graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from GPCR graph: ould lead to ineffective product or target candidates and exposure to compet…

BioAge Labs, Inc. Customers

TickerNameConfidenceEvidence
NVSEF Novartis AG 85% Reciprocal relationship from NVSEF graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from BIOA graph: royalties on net sales of license…
NVSEF Novartis AG 85% royalties on net sales of licensed products. Collaboration revenue of $2.8 million and $1.5 million was recognized under the Novartis Agreement in the three months ended March 31, 2026 and 2025. Duri…
LLY Eli Lilly and Company 72% novel APJ agonist antibody, as well as the filing of a U.S. provisional patent for novel small molecule APJ agonists. We intend to file the first Investigational New Drug application (IND) for an APJ…
LLY Eli Lilly and Company 72% Reciprocal relationship from LLY graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from LLY graph: Reciprocal relationship from BIOA graph: novel APJ agonist antibody, as well a…
MS-PE Morgan Stanley 72% Reciprocal relationship from MS-PE graph: Reciprocal relationship from BIOA graph: s, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately li…
MS-PK Morgan Stanley 72% s, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may still occur in the future. We regularly maintain cash balances at third…
MYGN Myriad Genetics, Inc. 72% Reciprocal relationship from MYGN graph: Reciprocal relationship from BIOA graph: ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in …
MYGN Myriad Genetics, Inc. 72% ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often invo…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from BIOA graph: ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in…
SNYNF Sanofi 72% ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often invo…
AMGN Amgen Inc. 62% Reciprocal relationship from AMGN graph: Reciprocal relationship from BIOA graph: ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in …
CO-LLC-MORGAN-STANLEY-JEFFERIES-LLC CO-LLC-MORGAN-STANLEY-JEFFERIES-LLC 62% s, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may still occur in the future. We regularly maintain cash balances at third…
DELAWARE-GENERAL-CORPORATION DELAWARE-GENERAL-CORPORATION 62% -party payor to not cover any of our product candidates, if approved, could reduce physician usage of our product candidates, and have a material adverse effect on our sales, results of operations an…
EMERGING-GROWTH-COMPANY EMERGING-GROWTH-COMPANY 62% , future revenue streams, research program or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financi…
IN-AMGEN-INC IN-AMGEN-INC 62% ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often invo…
LEERINK-PARTNERS-LLC LEERINK-PARTNERS-LLC 62% 2025 to $7.7 million for the three months ended March 31, 2026. The increase was primarily driven by a $0.6 million increase in personnel-related expenses, largely due to an increase in stock-based c…
NOVARTIS-PHARMA-AG NOVARTIS-PHARMA-AG 62% novel APJ agonist antibody, as well as the filing of a U.S. provisional patent for novel small molecule APJ agonists. We intend to file the first Investigational New Drug application (IND) for an APJ…
NVS Novartis AG 62% Reciprocal relationship from NVS graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from NVS graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from NVS grap…

BioAge Labs, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
BIOA-DEBT Debt stack $1.2M 90% Market cache reports total debt of $1.2M.
BIOA-DEBT-8200 Warrants outstanding: 214000 90% xbrl warrant detail from xbrl 2025-12-31.
BIOA-DEBT-8201 Xbrl Convertible 90% xbrl convertible detail from xbrl 2025-12-31.

BioAge Labs, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for BioAge Labs, Inc..

BioAge Labs, Inc. Ownership

HolderNameConfidenceEvidence
BIOA-OWNER-JANUS-HENDERSON-GROUP-PLC JANUS HENDERSON GROUP PLC 90% 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 146 tracked holders.

BioAge Labs, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
CBIO Crescent Biopharma, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
BNBX BNB Plus Corp. 100.00 2
FHTX Foghorn Therapeutics Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
AKTS Aktis Oncology, Inc. 100.00 2
CTNM Contineum Therapeutics, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
AMGN Amgen Inc. 100.00 1 ['customer']
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
DAWN Day One Biopharmaceuticals Inc 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
AXSM Axsome Therapeutics, Inc. 100.00 2
CRBP Corbus Pharmaceuticals Holdings, Inc. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
EDSA Edesa Biotech, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for BioAge Labs, Inc..

Unlock full BIOA data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
BIOA
Unlock BIOA Supply Chain Data
Verified relationships include:
CITIGROUP-GLOBAL-MARKETS-INCCITIGROUP-GLOBAL-MARKETS-INCSupplier92%
GOLDMAN-SACHS-CO-LLCGOLDMAN-SACHS-CO-LLCSupplier92%
NVSEFNovartis AGCustomer85%
NVSEFNovartis AGCustomer85%
+23 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →